Picture EBD Group World of Partnering Opportunities 650x100px

Document › Details

Immatics N.V.. (10/10/22). "Press Release: Immatics Reports Interim Clinical Data Update on ACTengine IMA203 TCR-T Monotherapy Targeting PRAME". Houston, TX & Tübingen.

	Organisation	Immatics N.V. (Nasdaq: IMTX)
	Group	Immatics (Group)
	Organisation 2	Trophic Communications GmbH
	Product	IMA203 TCR-T candidate targeting PRAME (ACTengine)
	Product 2	phase 1 study
	Person	Britten, Cedrik (Immatics 202006– CMO before GSK VP + Head of Oncology Cell Therapy Research Unit + BioNTech)
	Person 2	Mulder, Eva (Trophic Commincations 202005– Account Director before Uniqure)

Original document
accessed by [iito] on

Record changed: 2023-06-05

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Immatics (Group)

[1] Immatics N.V.. (10/24/23). "Press Release: Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy". Houston, TX & Tübingen....
[2] Immatics N.V.. (9/11/23). "Press Release: Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics". Cambridge, MA & Tübingen....
[3] Immatics N.V.. (7/24/23). "Press Release: Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb". Tübingen & Houston, TX....
[4] Immatics N.V.. (5/2/23). "Press Release: Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine IMA203 TCR-T Targeting PRAME". Houston, TX & Tübingen....
[5] MicrofluidX Ltd.. (5/2/23). "Press Release: MicrofluidX and Immatics Working Together on Automated End-to-End Bioprocessing for TCR-T Therapies". Stevenage & Houston, TX....
[6] Immatics N.V.. (5/1/23). "Press Release: Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration". Tübingen & Houston, TX....
[7] Immatics N.V.. (10/10/22). "Press Release: Immatics Announces $110 Million Underwritten Offering of Ordinary Shares". Houston, TX & Tübingen....
[8] Immatics N.V.. (9/10/22). "Press Release: Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022". Houston, TX & Tübingen....
[9] AiCuris Anti-infective Cures AG. (9/1/22). "Press Release: AiCuris Appoints Experienced Business Leader Dr. Sabrina Kuttruff-Coqui as Chief Financial Officer". Wuppertal....
[10] Immatics N.V.. (8/23/22). "Press Release: Immatics Announces First Cancer Patient Treated with Second-generation ACTengine TCR-T Candidate IMA203CD8 Targeting PRAME". Houston, TX & Tübingen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)